Alterity Therapeutics (ATHE) Stock Price, News & Analysis

Company Overview

Alterity Therapeutics is a clinical-stage biotechnology company focused on the development of novel treatments for neurological and neurodegenerative disorders. The company’s research portfolio centers on small molecules designed to target underlying disease mechanisms, with an emphasis on improving synaptic function and mitigating neuroinflammation.

Among its lead assets is trofinetide (NNZ-2566), a peptide analog derived from insulin-like growth factor 1, which is being investigated for the treatment of Rett syndrome and Fragile X syndrome in ongoing clinical trials. Another key program, PBT434, is an oral small molecule aimed at modulating metal-mediated oxidative stress, currently in early-stage development for Parkinson’s disease and related disorders.

Originally established in 1998 as Neuren Pharmaceuticals, the company rebranded to Alterity Therapeutics in 2023 to reflect its distinct focus on neurodegenerative conditions. Headquartered in Australia, Alterity conducts global clinical studies across North America, Europe and Australia, leveraging strategic partnerships to advance its pipeline toward regulatory milestones.

Key Stats

• Today's Range: $4.58 to $4.80
• 50-Day Range: $3.90 to $5.89
• 52-Week Range: $2.66 to $5.89
• Volume: 5,928 shs
• Average Volume: 9,798 shs
• Market Capitalization: $41.69 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $10.00
• Consensus Rating: Moderate Buy

Alterity Therapeutics Stock Analysis - MarketRank™

Alterity Therapeutics scored higher than 70% of companies evaluated by MarketBeat, and ranked 414th out of 902 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Alterity Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 4 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Alterity Therapeutics has a consensus price target of $10.00, representing about 112.8% upside from its current price of $4.70.

Amount of Analyst Coverage

Alterity Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Alterity Therapeutics are expected to grow in the coming year, from ($0.13) to ($0.05) per share.

Price to Book Value per Share Ratio

Alterity Therapeutics has a P/B Ratio of 1.52. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.39% of the float of Alterity Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Alterity Therapeutics has a short interest ratio ("days to cover") of 1.96, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Alterity Therapeutics has recently decreased by 44.54%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Alterity Therapeutics does not currently pay a dividend.

Dividend Growth

Alterity Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 1.3 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 4 news articles for Alterity Therapeutics this week, compared to 2 articles on an average week.

Search Interest

1 people have searched for ATHE on MarketBeat in the last 30 days.

MarketBeat Follows

1 people have added Alterity Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Alterity Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

38.80% of the stock of Alterity Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

2.14% of the stock of Alterity Therapeutics is held by institutions.

Company Calendar

• Today: 8/11/2026
• Canaccord Genuity's 46th Annual Growth Conference: 8/11/2026
• Next Earnings (Estimated): 8/28/2026
• Fiscal Year End: 6/30/2027

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:ATHE
• CIK: 1131343
• Web: www.alteritytherapeutics.com
• Phone: (139) 349-4906
• Fax: 61-3-9348-0377
• Employees: 10
• Year Founded: 1997

Price Target and Rating

• Average Price Target for Alterity Therapeutics: $10.00
• High Price Target: $16.00
• Low Price Target: $2.00
• Potential Upside/Downside: +112.8%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 21.97
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.10 per share
• Price / Book: 1.52

Miscellaneous

• Outstanding Shares: 8,870,000
• Free Float: 5,427,000
• Market Cap: $41.69 million
• Optionable: Not Optionable
• Beta: 0.27